Literature DB >> 4086238

Pathogenesis, diagnosis and therapy of induratio penis plastica (IPP).

H J Schneider, E W Rugendorff, C Röhrborn.   

Abstract

Induratio penis plastica (or Peyronie's disease) is a rather rare malady, probably caused by chronic inflammation or recurrent microtrauma. The most common complaints are pain on erection and difficulties in performing sexual intercourse. Conservative treatment having been rather disappointing until now, infiltration with superoxide dismutase (Orgotein) seems to be an important advance. In more than one half of the patients positive effects concerning pain, deviation of the penis and extension of the plaques have been achieved. If after two years of conservative therapy there is no improvement, surgical treatment is recommended.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4086238     DOI: 10.1007/BF02085410

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  9 in total

1.  Orgotein: a new antiinflammatory metalloprotein drug evaluation of clinical efficacy and safety in inflammatory conditions of the urinary tract.

Authors:  H Marberger; W Huber; G Bartsch; T Schulte; P Swoboda
Journal:  Int Urol Nephrol       Date:  1974       Impact factor: 2.370

2.  [Surgical treatment of plastic induration of the penis].

Authors:  G Stadie
Journal:  Z Urol Nephrol       Date:  1979-07

3.  Topical beta-aminopropionitrile in the treatment of Peyronie's disease.

Authors:  M Gelbard; A Lindner; M Chvapil; J Kaufman
Journal:  J Urol       Date:  1983-04       Impact factor: 7.450

4.  Classification of congenital and acquired penile deviation.

Authors:  A Kelâmi
Journal:  Urol Int       Date:  1983       Impact factor: 2.089

5.  Orgotein, a new drug for the treatment of Peyronie's disease.

Authors:  G Bartsch; K B Menander-Huber; W Huber; H Marberger
Journal:  Eur J Rheumatol Inflamm       Date:  1981

6.  Evaluation of the surgical management of Peyronie's disease.

Authors:  J M Palomar; H Halikiopoulos; R Thomas
Journal:  J Urol       Date:  1980-05       Impact factor: 7.450

7.  [Clinical experiences with orgotein in urologic diseases].

Authors:  J Frick; C Danner; G Kunit
Journal:  Eur J Rheumatol Inflamm       Date:  1981

8.  Peyronie's disease: experience of local treatment with Orgotein.

Authors:  H Gustafson; B Johansson; F Edsmyr
Journal:  Eur Urol       Date:  1981       Impact factor: 20.096

9.  Peyronie's disease.

Authors:  B H Smith
Journal:  Am J Clin Pathol       Date:  1966-06       Impact factor: 2.493

  9 in total
  2 in total

1.  Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging.

Authors:  O Polat; O Gül; I Ozbey; M Ozdikici; Y Bayraktar
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

2.  US Imaging in Peyronie's Disease.

Authors:  Kiriaki Kalokairinou; Charalampos Konstantinidis; Marilena Domazou; Theodoros Kalogeropoulos; Prodromos Kosmidis; Aristomenis Gekas
Journal:  J Clin Imaging Sci       Date:  2012-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.